This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nademanee, K. Articles by Hershman, J. Search for Related Content PubMed PubMed Citation Articles by Nademanee, K. Articles by Hershman, J.

Circulation, Vol 66, 202-211, Copyright © 1982 by American Heart Association

ARTICLES

Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy

K Nademanee, BN Singh, JA Hendrickson, AW Reed, S Melmed and J Hershman

We studied the antiarrhythmic effects of amiodarone, 600-1400 mg/day, in 18 patients with refractory arrhythmias, and related to drug efficacy and side effects to serum levels of T4, reverse T3 (rT3) and the QTc interval. In the 11 patients with ventricular arrhythmias, premature complexes were reduced by 90-98%, and complex ectopy and runs of ventricular tachycardia were abolished; in the seven patients with paroxysmal atrial flutter, there were no recurrences on stable drug therapy. The QTc lengthened by 11.6% (p less than 0.01), T4 increased by 31.6-63.3% (p less than 0.001) and rT3 increased by 82.9-176.8% (p less than 0.001) as a function of dose and duration of amiodarone therapy. A close correlation was found between rT3 (normal up to 50 ng/dl) and drug efficacy and some of the drug side effects; arrhythmia suppression occurred at levels of 55-100 ng/dl, and some of the known side effects at levels of 100-110 ng/dl. When amiodarone was stopped in nine patients, the changes in QTc, T4 and rT3 regressed toward normal and arrhythmia recurred in eight 2-20 weeks (mean 7.4 weeks) and when rT3 levels fell below 55 ng/dl; arrhythmia resuppression was achieved 3- 28 days (mean 11 days) after resumption of amiodarone therapy. The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days). The data suggest that rT3 levels may be useful in monitoring the efficacy and certain side effects of amiodarone.

This article has been cited by other articles:

				D. B. McElhinney, A. J. Parry, V. M. Reddy, F. L. Hanley, and P. Stanger Left Pulmonary Artery Kinking Caused by Outflow Tract Dilatation After Transannular Patch Repair of Tetralogy of Fallot Ann. Thorac. Surg., April 1, 1998; 65(4): 1120 - 1126. [Abstract] [Full Text] [PDF]

				I. Kodama, K. Kamiya, and J. Toyama Cellular electropharmacology of amiodarone Cardiovasc Res, July 1, 1997; 35(1): 13 - 29. [Full Text] [PDF]

				H. H. ROTMENSCH, B. BELHASSEN, B. N. SWANSON, D. SHOSHANI, S. R. SPIELMAN, A. J. GREENSPON, A. M. GREENSPAN, P. H. VLASSES, and L. N. HOROWITZ Steady-State Serum Amiodarone Concentrations: Relationships with Antiarrhythmic Efficacy and Toxicity Ann Intern Med, October 1, 1984; 101(4): 462 - 469. [Abstract] [PDF]

				J. A. Amico, V. Richardson, B. Alpert, and I. Klein Clinical and Chemical Assessment of Thyroid Function During Therapy With Amiodarone Arch Intern Med, March 1, 1984; 144(3): 487 - 490. [Abstract] [PDF]

				K. NADEMANEE, B. N. SINGH, J. HENDRICKSON, V. INTARACHOT, B. LOPEZ, G. FELD, D. S. CANNOM, and J. L. WEISS Amiodarone in Refractory Life-Threatening Ventricular Arrhythmias Ann Intern Med, May 1, 1983; 98(5_Part_1): 577 - 584. [Abstract] [PDF]